|
LA JOLLA PHARMACEUTICAL PRESENTS AT
NEEDHAM & COMPANY BIOTECHNOLOGY CONFERENCE
SAN DIEGO, May 22, 2002 -- La Jolla
Pharmaceutical Company (Nasdaq: LJPC)
today announced that Steven B. Engle,
its Chairman and CEO, will discuss the
Company's Phase III clinical trial in
lupus and its Phase I/II clinical trial
in antibody-mediated thrombosis at the
Needham Biotechnology Conference in
New York on Tuesday, June 4, 2002 at
2:30 p.m. EDT.
"With 250 patients randomized,
enrollment continues on schedule for
the Phase III clinical trial of our
lead clinical compound, LJP 394, for
lupus renal disease," said Mr.
Engle. "Our lupus and antibody-mediated
thrombosis drug candidates are designed
to provide highly specific approaches
to treating the underlying cause of
these two life-threatening autoimmune
diseases."
La Jolla Pharmaceutical Company is
a biotechnology company leading the
development of therapeutics for antibody-mediated
autoimmune diseases afflicting several
million people in the United States
and Europe. The Company is conducting
a Phase III trial of LJP 394 in patients
with lupus kidney disease, a leading
cause of sickness and death in these
patients. The Company is also conducting
a Phase I/II trial of LJP 1082 for the
treatment of antibody-mediated thrombosis,
a condition in which patients suffer
from recurrent stroke, deep-vein thrombosis
and other thrombotic events. The Company's
common stock is traded on The Nasdaq
Stock Market under the symbol LJPC.
For more information about the Company,
visit our Web site: http://www.ljpc.com.
Patients interested in the Phase III
lupus trial may call 1-800-30-LUPUS
for information.
Except for historical statements, this
press release contains forward-looking
statements involving significant risks
and uncertainties, and a number of factors,
both foreseen and unforeseen, could cause
actual results to differ materially from
our current expectations. Our analyses
of clinical results of LJP 394, our drug
candidate for the treatment of systemic
lupus erythematosus ("lupus"),
and LJP 1082, our drug candidate for the
treatment of antibody-mediated thrombosis
("thrombosis"), are ongoing
and future analyses could result in a
finding that these drug candidates are
not effective in large patient populations,
do not provide a meaningful clinical benefit
or may reveal a potential safety issue
requiring us to develop new candidates.
Our blood test to measure the binding
affinity for LJP 394 is experimental,
has not been validated by independent
laboratories, may require regulatory approval
and may be necessary for the approval
and the commercialization of LJP 394.
Our other potential drug candidates are
at earlier stages of development and involve
comparable risks. Analysis of our clinical
trials could have negative or inconclusive
results. Any positive results observed
to date may not be indicative of future
results. Even if results are promising,
the U.S. Food and Drug Administration
("FDA") may require additional
clinical trials. The Company's ability
to develop and sell its products in the
future may be affected by the intellectual
property rights of third parties. Additional
risk factors include the uncertainty of:
obtaining required regulatory approvals;
successfully marketing products; receiving
future revenue from product sales or other
sources such as collaborative relationships;
future profitability; the need for additional
financing; our dependence on patents and
other proprietary rights; FDA approval
of our manufacturing facilities; the increase
in capacity of our manufacturing capabilities
for possible commercialization; and our
lack of marketing experience. Readers
are cautioned to not place undue reliance
upon forward-looking statements, which
speak only as of the date hereof, and
we undertake no obligation to update forward-looking
statements to reflect events or circumstances
occurring after the date hereof. Interested
parties are urged to review the risks
described in our other reports and registration
statements filed with the Securities and
Exchange Commission from time to time,
including the report on Form 10-K for
the year ended December 31, 2001.
Copyright © 2008, La Jolla Pharmaceutical Company | Terms
of Use
|